Estimating the potential malaria morbidity and mortality avertable by the President's Malaria Initiative in 2025: a geospatial modelling analysis

Tasmin L. Symons[1,2], Jailos Lubinda[2], Michael McPhail[2], Adam Saddler[2], Mauricio van den Berg[2], Hunter Baggen[2], Yuval Berman[2], Sarah Hafsia[2], Rubi Jayaseelen[2], Punam Amratia[3], Annie Browne[2], Ewan Cameron[1,2], Camilo Vargas[2], Susan F. Rumisha[3,1], Nick Golding[4], Daniel J. Weiss[1,2], Peter W. Gething[1,2]

1. School of Population Health, Curtin University, Bentley, Western Australia.
2. Malaria Atlas Project, The Kids Research Institute Australia, Nedlands, Western Australia.
3. Malaria Atlas Project, Ifakara Health Institute, Dar es Salaam, Tanzania.
4. School of Physics, Mathematics and Computing, University of Western Australia, Western Australia

Abstract

Background

Since its inception in 2005, the President's Malaria Initiative (PMI) has played a major role in the reductions in malaria morbidity and mortality witnessed across Africa. With the status of PMI funding and operations currently uncertain, this study aimed to quantify the impact that a fully-functioning PMI would have on malaria cases and deaths in Africa during 2025.

Methods

We combined detailed spatio-temporal information on planned 2025 PMI and non-PMI malaria commodity procurement and distribution in Africa with spatio-temporal Bayesian models of intervention coverage and *Plasmodium falciparum* transmission and burden in Africa. By comparing coverage scenarios with and without planned PMI contributions we estimated the number of malaria cases and deaths PMI would avert in 2025.

Findings

We estimated that business-as-usual PMI contributions to vector control, seasonal chemoprevention, and routine malaria treatment in Africa would avert in 2025 14·9M (95% uncertainty interval 12·5M – 17·8M) malaria cases and 107,000 (71,000 – 166,000) deaths. This represents 12·6% (11·1 – 14·2%) and 39·0% (37·1 – 40·4%), respectively, of the total burden of malaria morbidity and mortality in PMI's focus geographies across 27 African countries. These estimates do not account for the additional impact of PMI-supported provision of diagnostics or severe case management commodities, nor preventive treatment for pregnant women which would add further to the averted burden.

Interpretation

PMI investment in supporting procurement and distribution of malaria control commodities would translate directly into millions of malaria cases averted and a hundred thousand lives saved across its focus geographies in Africa across 2025.

Funding

National Health and Medical Research Council, Australia

Research in context

Evidence before this study

We searched PubMed on 25 February 2025 with the search term "President's Malaria Initiative" AND (impact OR evaluation) AND (burden OR malaria cases OR malaria deaths). 102 results were returned, of which four directly addressed the question of PMI-attributable impact on malaria burden across all its focus geographies. One focussed solely on case-management and did not provide quantitative results[1]. A study focussing on mortality found a strong association between PMI investment and declines in all-cause infant mortality[2]. Another study used a generalised estimating equation approach to assess PMI's impact, concluding a strong association between PMI spending and reductions in malaria burden[3]. A 2017 study used a mechanistic malaria model to estimate PMI's historic contribution to reductions in malaria morbidity and mortality, with future projections to 2020[4].

Added value of this study

In this study we synthesised the most up-to-date information of all-funder volumes of key malaria control interventions (ITN, IRS, ACT, SMC) with PMI data on planned volumes and spatial targeting of funding in 2025 to derive near-real-time projections of malaria control intervention coverage in Africa under two scenarios: a business-as-usual scenario in which PMI commodities procured and distributed as previously planned versus a 'no-PMI' scenario in which PMI funding and technical assistance is absent. These scenario-based estimates of coverage were propagated through an empirical geospatial malaria model, coupled to mechanistic models of clinical incidence, in order to estimate the number of malaria infections, clinical cases, and deaths PMI activities could expect to avert in Africa in 2025.

Implications of all available evidence

PMI is a key contributor to malaria control efforts in Africa, and as such its impact on averting childhood mortality has been demonstrated repeatedly. Here, using empirically-derived estimates of malaria control impact, combined with detailed scenarios of intervention coverage with- and without- PMI support, we isolated the contemporary impact of PMI activities on malaria morbidity and mortality in Africa in 2025. Our findings suggest that PMI support is critical to maintaining suppression of malaria transmission in its focus geographies.

Introduction

Over the past 20 years, malaria control has greatly reduced malaria transmission, cases, and deaths in Africa[5,6]. A catalyst of this achievement has been the growth in international development assistance for health, including the launch in 2002 of the Global Fund followed in 2005 by the US President's Malaria Initiative (PMI). By 2023 PMI supported malaria control in 31 countries (27 in Africa), and disbursed USD$777·7M[7]. That investment enabled, in the 2023 US financial year, the procurement of 36·8M insecticide treated bednets (ITNs), 63·3M doses of the effective antimalarial drug artemisinin-based combination therapy (ACT), indoor residual spraying (IRS) of insecticides to protect 15·5M people, and 48M treatments of seasonal malaria chemoprevention (SMC) to protect children in locations with intense malaria seasonality[7]. Most of this financial support was directed to the highest burden regions of malaria-endemic Africa[6,7]. In addition to core vector control and treatment, PMI has also supported the large-scale deployment of preventive treatment for pregnant women , the scale-up of rapid diagnostic tests (RDTs) to support accurate point-of-care diagnosis, and other wide-ranging technical support to health personnel working in malaria-endemic countries. The immediate and longer-term future of PMI is currently uncertain, and the extent to which it's planned support for malaria control across Africa in 2025 will eventuate is not clear. Given the large proportional contribution of PMI to overall malaria control efforts in the highest-burden regions, the presence or absence of PMI financing and operations has the potential to significantly impact total malaria burden in Africa. Estimates of the overall potential impact of PMI in 2025, how this varies by country, and the relative contributions of different intervention tools, can therefore help inform ongoing decision making at international and national levels.

Various approaches have been developed to estimate - retrospectively or prospectively - the malaria burden averted by investments in malaria control efforts[8,9]. An initial challenge is to understand how those investments have translated into coverage of malaria control interventions. A common method is to assume that funds invested translate proportionally into coverage achieved, enabling coverage to be predicted using simple arithmetic based on commodity unit costs multiplied by funds available. While reasonable for some interventions, this assumption is not always valid and evidence demonstrates, for example, that incremental increases in coverage of ITNs becomes progressively more expensive to achieve above a certain threshold[10,11]. In this study, we deploy a range of coverage models that more explicitly

link investments to commodity volumes to deployment and ultimately to population coverage.

The second challenge is to estimate the likely impact interventions have on malaria at a given

level of coverage. In this study we build on the modelling architecture of the Malaria Atlas

Project (MAP)[12] used to produce annually updated estimates of malaria burden and trends for

the WHO World Malaria Report[6] and Global Burden of Disease study[13]. We use this framework

to generate modelled estimates of the potential of PMI to avert malaria cases and deaths in

2025. We define a business-as-usual scenario in which we reconstruct malaria control

commodity procurement and distribution as previously planned for 2025 and compare this to

a scenario in which activities supported by PMI do not take place.

Methods

Figure 1 provides a schematic overview of our analysis, which comprised the following steps.

First, we assembled data on past and planned malaria control commodity procurement and

distribution from both PMI and non-PMI funding sources and focusing on ITNs, ACTs, SMC,

and IRS. Second, we used coverage models to estimate subnational coverage of each of these

interventions in 2025 in scenarios with and without contributions from PMI. Third, we used an

established Bayesian geostatistical model to predict infection prevalence across Africa in 2025

under both scenarios and, fourth, converted these into corresponding estimates of malaria

clinical incidence and mortality. These steps are described in more detail below and with

supporting methodological descriptions in the appendix.

Determining malaria control coverage attributable to PMI in 2025

The Roll Back Malaria Initiative (RBM) hosts programmatic and financial gap analysis tables

that include data – by malaria-endemic country – detailing the number of ITNs financed for

planned distribution in 2024 and 2025, reflecting a business-as-usual (BAU) scenario[14]. These

numbers are inclusive of all sources of funding, including PMI. At the time of analysis, this

information was current as of 17 December 2024. Separately, we sourced historical ITN

distribution data from national malaria control programs (NMCPs) for the period 2000-2023,

primarily via World Health Organization reporting[6]. We then refined the financed 2025 annual

distribution volumes into inferred quarterly volumes based on information on the planned

timings of mass campaigns available via the 'ITN Mass Campaign Tracker' resource

maintained by the Alliance for Malaria Prevention[15]. The fraction of ITNs likely to be

distributed through mass-campaign distributions versus routine distribution channels (for

example via health facilities, antenatal clinics, schools, community health workers) was

inferred based on this ratio for each country in historical data. We then estimated for each

country the fraction of all ITNs financed for 2025 that are financed by PMI. Data on planned

volumes of ITNs procured or distributed by PMI versus other funders in 2025 were extracted

from PMI FY2024 Malaria Operational Plans (MOPs)[16], together with details on (i) the

geographical extent of PMI support where this was subnational, and (ii) where PMI provides

financial support to facilitate distribution of ITNs purchased by other donors (including in

Cameroon and Nigeria). The resulting inferred PMI-financed proportions were then then

subtracted from the BAU volumes to define a 'no PMI' scenario (see appendix table S1). Next,

both the BAU and no-PMI scenario ITN volumes were entered into an established dynamic

coverage model[10,11] which transformed them into monthly estimates of ITN coverage (access

and use) at subnational level for 2025. The model took into account ITNs already distributed

to households in preceding years and their likely rate of loss.

Data on the volumes of ACTs financed for distribution in 2025 from all funding sources, and

the fraction supported by PMI, were extracted from the PMI FY2024 MOPs. These documents

also provided delineation, where relevant, of the subnational regions in which PMI provide this

support. The MOPs also detail past years distributions and end-of-year stock-on-hand.

Combining these data elements allowed us to generate inferred subnational ACT distribution

volumes for 2025 under the BAU (i.e. including planned PMI contributions) and no-PMI

(excluding those contributions) scenarios (see appendix figure s3). Stock-on-hand at the outset

of 2025 was considered available for distribution even in the no-PMI scenario. We then

converted these distribution scenarios into estimated treatment coverages (i.e. the fraction of

clinical malaria cases receiving effective treatment) as follows. For the BAU scenario we used

pre-existing coverage estimates developed by MAP for the annual WHO World Malaria

Report[12,6] that consider rates of care seeking, access to antimalarial drugs, and the time-varying

efficacy of different drug classes. We used the estimates for 2024 as a proxy for 2025, assuming

coverage would be similar under BAU. Treatment coverage under the no-PMI scenario in 2025

was then computed by reducing public-sector treatment rates in proportion to the fraction of all

ACTs financed in 2025 by PMI per subnational unit. We did not extend this analysis to include

the possible effects of reduced availability of rapid diagnostic tests (RDTs) under the no-PMI

scenario. In reality, reduced access to confirmatory diagnosis would further compromise levels

of access to effective antimalarial treatment by reducing appropriate targeting of limited ACT
stock to confirmed cases.

Areas with planned SMC campaigns supported by PMI under BAU in 2025 were identified
using data from the FY2024 PMI MOPs, augmented with data reported by NMCPs to WHO[6].
Within those areas, coverage under BAU was assumed to be the same as that estimated for
2024 based on a compilation of post-campaign coverage surveys undertaken by NMCPs and
by Malaria Consortium[17,18]. The timing and number of cycles were assumed to be the same as
in 2024 and the target population was assumed to be strictly children under 59 months. The no-
PMI scenario was then simply defined as having zero SMC coverage in 2025 in the PMI-
supported SMC areas.

The most recent MAP estimates of IRS coverage (for the year 2023) were obtained, which are
based on subnational data on spray campaigns reported by NMCPs to WHO[6], reported by PMI
in national 'End of Spray Reports' (e.g. PMI VectorLink reports[19,20]), or from other country-
specific sources[21]. We used this 2023 coverage to represent our BAU scenario for 2025. Details
of the subset of planned IRS spraying supported by PMI in 2025 were extracted from PMI
FY2024 MOPs[16]. The no-PMI scenario was then defined as having zero IRS coverage in 2025
in those IRS target areas supported by PMI.

Determining epidemiological impact of PMI-attributable coverage

We propagated the BAU and no-PMI intervention coverage scenarios for ITNs, ACTs, SMC,
and IRS through a series of established models to generate corresponding estimates of infection
prevalence, clinical case incidence, and malaria mortality at 5×5 km resolution and by month
across 2025.

First, we fitted a Bayesian geostatistical model to historical data on malaria infection
prevalence, intervention coverage, and environmental and socioeconomic covariates from
2000-2023. Prevalence data comprised 59,516 cross-sectional observations of malaria
infection prevalence age-standardised to the 2-10 year old age group (i.e. *P. falciparum* parasite
rate, $PfPR_{2-10}$), as compiled on a rolling basis by MAP[12] and collected predominantly through
cross-sectional surveys such as those conducted by the Demographic and Health Surveys

Program (DHS)[22]. Observations were standardised for diagnostic type[23] and age[24] before
modelling. Geotemporal intervention coverage estimates from 2000-2023 were derived from
the exiting MAP coverage models referenced above and described in detailed previously[13].
Geotemporal data on environmental and socio-economic covariates capturing climatic,
landcover, and infrastructural variables were also derived from existing MAP catalogues as
described previously[13]. The geostatistical modelling framework used here is described
extensively elsewhere[5,13]. In brief, the effect on PfPR$_{2-10}$ of: (i) the physical and insecticidal
components of ITN coverage, as a function of baseline transmission intensity and trends in
pyrethroid resistance; (ii) access to effective antimalarial treatment; and (iii) IRS coverage was
determined empirically using a hierarchical Bayesian spatio-temporal model. The model
included additional terms controlling for (iv) the environmental and socioeconomic predictors;
(v) underlying baseline endemicity; and (vi) unexplained variation accounted for using a
spatio-temporal random field with separable Matérn-5/2-AR(1) covariance structure and
independent country-level random effects. For this analysis, we updated the model to explicitly
include the effect of insecticide resistance (see appendix section 2.2) and leverage new remote-
sensing imagery to better resolve urban-rural gradients of risk. Fitted parameters are shared in
the appendix, tables S3 and S4. After five-fold cross-validation, out-of-sample mean squared
error was 2·1%, mean absolute error was 9·0%, and correlation between observed and
predicted PfPR$_{2-10}$ was 0.80. The model was fit in R v.4.4.1 using INLA v.24.06.27[25,26]. The
fitted model, which includes detailed terms characterising the effects of each intervention class,
was then used in a final step to predict PfPR$_{2-10}$ at 5×5 km resolution for each month of 2025
across Africa. Two predictions were carried out to reflect intervention coverages under both the
BAU and no-PMI scenarios described above. For both scenarios, environmental and
socioeconomic covariates were fixed at 2023 levels, the most recent full year of available data.

The BAU and no-PMI PfPR$_{2-10}$ predictions for 2025 were used to generate corresponding
geotemporal estimates of annual *P. falciparum* clinical incidence rate using an established
natural history model[27]. Annual estimates were disaggregated to monthly values using a
seasonality model based on compiled observations of clinical malaria seasonality across
Africa[28]. We additionally accounted for the impact on clinical incidence of SMC using our
modelled SMC coverage combined with observations of SMC effectiveness under routine
implementation pooled across sites in seven West African countries[29] (see appendix section
2.3.1). Malaria mortality in 2025 under the BAU and no-PMI scenarios was determined by first

combining the geotemporal estimates of clinical cases and treatment rates to derive untreated

cases. We then applied to those untreated case estimates an untreated case fatality rate derived

from the World Malaria Report[30], including upper and lower bound estimates. Note that this

approach captures two mechanisms by which antimalarial treatment averts mortality: via direct

impact on $PfPR_{2\text{-}10}$, which reduces clinical incidence rates, and then additionally by reducing

the fraction of clinical cases that progress to death.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data

interpretation, or writing of the report. The corresponding author had full access to all the data

in the study and had final responsibility for the decision to submit for publication.

Results

Intervention coverage

Our compiled data on planned procurement and distribution indicated that under business-as-

usual PMI would provide 44 million ITNs in 2025. An additional 15 million ITNs funded by

the Against Malaria Foundation for Nigeria and Cameroon are reliant on PMI logistical support

for distribution[31,32]. In total, these volumes represent 35% of the 169M ITNs planned for

distribution in 2025 across the 25 African PMI focus countries included in this study. We

estimated that these ITNs would contribute 10.1 percentage points (pp) to population coverage

(i.e. use) by the end of 2025 across the PMI focus countries. Impact varies considerably by

country with up to a 75·5 pp effect on coverage in PMI focus areas of Cameroon (Figure 2A)

and effects exceeding 20 pp in Sierra Leone, Nigeria (PMI focus states), Burundi, Zimbabwe,

and Cameroon (Figure 2A). Data on planned ACT procurement and distribution indicated that

PMI would finance 71 million doses of the drug across its African focus regions in 2025 under

business-as-usual, representing 52% of total ACT procurement in those regions. We estimated

that these drugs would contribute 12·0 pp to the fraction of clinical malaria cases receiving

effective treatment. Some countries are proportionally more reliant on PMI-funded ACTs than

others, with PMI contributing over 20 pp to effective treatment rates in Zambia, Senegal,

Burundi, and PMI focus provinces of Angola, (Figure 2B). Compiled data indicates that under

business-as-usual PMI would contribute 12·3 pp to under-five population coverage of SMC

across all areas targeted for this intervention in Africa in 2025. In specific subnational

geographies where PMI would concentrate SMC support, this figure is often greater than 75

pp (Figure 2C). PMI was scheduled to be a relatively minor contributor to IRS campaigns in

Africa in 2025, with a business-as-usual contribution of 4·9 pp to annualised coverage across

regions targeted continent-wide (Figure 2D).

Malaria cases and deaths

We estimate that PMI procurement and distribution of malaria control commodities, as planned

under business-as-usual operations for 2025, would avert 14·9M (95% uncertainty interval

12·5M – 17·8M) clinical malaria cases and save 107,000 (71,000 – 166,000) lives across that

year. (Table 1, Figure 3A,B). Burden averted by month is slightly greater in the latter half of

the year, driven in part by the availability of pre-existing stock-on-hand for ACTs which reduce

the impact of the no-PMI scenario in the first few months of 2025. In addition, the timing of

planned PMI-funded ITN and SMC campaigns, which typically occur in quarters three and

four for Sahelian countries due to seasonal variations in transmission intensity, means greater

impact in these later months. Our decomposition by intervention type (Figure 3B,C) indicated

that PMI-funded ACT provision formed the largest contribution to both cases (59%) and deaths

(87%) averted, followed by ITNs (23% of cases, 7% of deaths) and SMC (18% of cases, 6%

of deaths). At national-level, we estimate business-as-usual PMI activities would save the

largest number of lives in PMI focus regions of Nigeria (20,555; 14,434 - 30,318), Democratic

Republic of the Congo (11,261; 6,498 - 20,544), and Burundi (11,625; 7,517 - 18,974),

corresponding to densely-populated high-burden countries with extensive PMI support (Table

1).

Discussion

At a time of ongoing policy reorientation, it is essential to make available to decision makers

reliable measures of the impact of investments in global health. Here we demonstrate that a

fully functioning PMI would likely save around 15M malaria cases and avert around 100,000

malaria deaths in Africa in 2025. These estimates do not rely on simple extrapolations of lives-

saved-per-dollar but are instead built up from a detailed reconstruction of planned procurement

and distribution activities for the major classes of malaria control commodity, the proportional

geographically-specific contribution of PMI to that commodity provision, the way those

commodities drive population coverage, and the way that coverage impacts malaria

transmission and burden. This granularity allows the necessary sophistication to capture the

differential effects of each intervention class, to take into account control interventions already

in place or available for distribution at the onset of the year, and to acknowledge heterogeneity

in underlying malaria risk across the continent and how this influences intervention impact.

The results presented here must be interpreted in the context of several limitations. First, while

we focus on PMI-funded commodity procurement, we do not explicitly account for PMI

support to logistics and supply chain management, instead assuming that changes in coverage

stem only from reduced input commodity volumes. Second, we do not account for PMI support

for RDTs. In practice, RDT stock-outs would result in reversion to presumptive malaria

diagnosis which would translate into a higher fraction of ACTs being prescribed to non-malaria

cases. This would not only impair appropriate management of non-malaria causes but would

place further strain on ACT stocks. Reduced confirmatory diagnosis also means surveillance

data would decline in quality – impairing future monitoring of malaria trends. Third, when

estimating mortality effects, we take into account only changes to overall case incidence and

to rates of first-line treatment of presenting uncomplicated clinical cases, implicitly assuming

the case-fatality rate among untreated cases remains constant. This neglects any contribution

of PMI to supporting quality management of severe malaria cases - for example via

procurement of injectable artesunate. Fourth, we do not account for any present or planned

PMI support for the implementation of vaccination with the RTS,S/AS01 or R21/Matrix-M

vaccines. Fifth, we do not account for healthcare personnel directly supported by PMI. Most

importantly, this includes around 100,000 community health workers[7] – whose efforts have

demonstrably improved access to timely malaria case management in rural and remote

communities in many PMI focus countries[33]. Finally, we do not account for a range of

additional activities supported by PMI, that include strengthening of disease and entomological

surveillance systems, and monitoring of insecticide and drug resistance. It is important to note

that nearly all of these limitations imply our estimates are conservative with respect to the

number of cases and deaths averted. Moreover, PMI investments in malaria control

commodities in 2025 will, by design, deliver longer-term lives-saved beyond 2025: ITNs are

typically retained for multiple years, whilst efficient but front-loaded procurement of ACTs

mitigates stock-out risk.

This analysis indicates that PMI investment in supporting procurement and distribution of malaria control commodities would translate directly into millions of malaria cases averted and a hundred thousand lives saved in its 27 countries of operation in Africa across 2025.

Contributors

PWG and TLS conceptualised the study, led data analysis and wrote the first draft of the manuscript. JL, MM, AS, MV, HB, YB, SH, RJ, PA, AB, EC, CV, SFR, NG, DJW contributed to data curation and compilation and contributed to data analysis. All authors had full access to the data, contributed to review and approved the final version of the manuscript.

Data sharing

Data on commodity funding and distribution, malaria prevalence and intervention coverage used in this analysis are available in the public domain via the cited sources. All PMI-focus-geography level results are available within the main text and supplementary material. Other summarisations are available upon request to the authors.

Declaration of interests

All authors declare no competing interests.

Acknowledgments

This work is supported by the National Health and Medical Research Council, Australia (2025280).

Figures and Tables

 Table 1. Estimated mean malaria cases and deaths averted in Africa by PMI in 2025, with 95%

 uncertainty intervals. DRC = Democratic Republic of the Congo. Africa estimate corresponds

 to the sum across all PMI focus geographies.

Country	Malaria cases averted	Malaria deaths averted
Angola (PMI focus provinces)	192,805 (137,861 - 253,599)	1,861 (1,072 - 3,392)
Burundi	1,191,342 (887,968 - 1,500,490)	11,625 (7,517 - 18,974)
Benin	276,602 (240,846 - 312,546)	1,274 (886 - 1,845)
Burkina Faso	936,181 (805,773 - 1,103,585)	7,291 (4,836 - 11,446)
Cote d'Ivoire	508,139 (385,410 - 662,729)	2,700 (1,860 - 4,100)
Cameroon (PMI focus regions)	1,523,146 (1,361,296 - 1,665,642)	4,413 (3,283 - 5,994)
DRC (PMI focus provinces)	1,425,503 (1,113,352 - 1,782,909)	11,261 (6,498 - 20,544)
Ethiopia	205,834 (162,190 - 251,441)	433 (130 - 1,002)
Ghana	251,734 (223,793 - 276,212)	602 (512 - 712)
Guinea	199,300 (172,379 - 224,015)	445 (338 - 595)
Kenya	165,317 (133,984 - 195,217)	1,188 (992 - 1,477)
Liberia	132,913 (99,843 - 170,667)	1,223 (761 - 1,973)
Madagascar	57,960 (44,083 - 72,596)	273 (87 - 589)
Mali	541,140 (446,018 - 648,314)	2,900 (2,080 - 3,962)
Mozambique	558,507 (398,012 - 725,353)	5,202 (2,905 - 9,842)
Malawi	391,170 (283,270 - 512,850)	2,643 (1,954 - 3,853)
Niger	807,810 (588,149 - 1,106,120)	8,043 (5,331 - 12,317)
Nigeria (PMI focus states)	2,948,054 (2,573,072 - 3,391,631)	20,555 (14,434 - 30,318)
Rwanda	140,791 (107,900 - 175,043)	832 (625 - 1,102)
Senegal	1,009,257 (718,759 - 1,328,017)	7,915 (2,804 - 16,848)
Sierra Leone	177,269 (145,311 - 209,141)	1,171 (711 - 1,890)
Togo	5,323 (4,167 - 6,373)	9 (6 - 13)
Tanzania	698,509 (507,781 - 865,395)	9,737 (7,699 - 12,804)
Uganda	176,178 (145,771 - 211,681)	239 (164 - 378)
Zambia	392,486 (292,308 - 495,434)	3,610 (2,722 - 4,982)
Zimbabwe	7,066 (5,030 - 9,365)	20 (6 - 47)
Africa (PMI focus)	**14.9M (12.5M – 17.8M)**	**107,000 (71,000 – 166,000)**

375
376
Figure 1. Schematic summary of methodological framework. Blue rectangles represent input
datasets, some of which are modelled results from preceding analyses. Orange rectangles
represent modelling steps. Green rectangles are the results of the analysis. ITN=insecticide-
treated net. IRS = Indoor Residual Spraying, SMC = Seasonal Malaria Chemoprevention.
*Pf*PR=*Plasmodium falciparum* parasite rate. BAU = business-as-usual scenario. noPMI = PMI-
funded interventions removed scenario.

Figure 2. Projected contributions of PMI in 2025 under business-as-usual (BAU) to each

intervention class considered in this study. (A) Percent-point difference in access to insecticide

treated bednets between BAU and no-PMI scenarios, projected in December 2025. Inset shows

BAU and no-PMI scenario projected ITNs in households, January-December 2025. (B)

Percentage-point difference in the proportion of clinical malaria cases receiving effective

treatment between BAU and no-PMI scenarios, projected in December 2025. Inset shows BAU

and no-PMI scenario projected effective treatment rates of clinical malaria cases, January-

December 2025. (C) Spatial extent of Seasonal Malaria Chemoprevention projected in 2025,

classified by funding support (PMI vs other funders). Inset shows BAU and no-PMI scenario

projected numbers of infants (under five) protected by SMC, January-December 2025. (D)

Spatial extent of IRS projected in 2025, classified by funding support (PMI vs other funders).

Inset shows BAU and no-PMI scenario projected area (in km^2) protected by IRS, January-

December 2025. SMC = Seasonal Malaria Chemoprevention; BAU = business-as-usual; PMI

= President's Malaria Inititative.

400
401
Figure 3. Estimates of malaria burden averted by PMI in Africa in 2025 with 95% uncertainty
intervals; (A) Number of *Plasmodium falciparum* clinical cases (in millions), by month, with
blue representing business-as-usual projection and red with PMI-funded interventions
removed; (B) the number of *P. falciparum* deaths, by month, with colour scheme as in (A).
Plotted monthly estimates are off-set in the no-PMI scenario for presentation and ease of
interpretation; (C) Number of *P. falciparum* clinical cases (in millions) averted by PMI-funded
interventions, by month of 2025, disaggregated by intervention class. (D) Number of *P.*
falciparum deaths averted by PMI-funded interventions, by month of 2025, disaggregated by
intervention class. Vector control consists of both coverage with Insecticide Treated Bednets
and Indoor Residual Spraying; SMC = Seasonal Malaria Chemoprevention.
412
413

414   References

1. Barat LM, Whitehurst N, Venkatesan M, Connolly K, Yamo E, Psychas P, Bernard YM. The US President's Malaria Initiative's support for improving the quality of malaria case management services: fifteen years of progress and learning. The American Journal of Tropical Medicine and Hygiene. 2023 Nov 27;110(3 Suppl):1.

2. Jakubowski A, Stearns SC, Kruk ME, Angeles G, Thirumurthy H. The US President's Malaria Initiative and under-5 child mortality in sub-Saharan Africa: A difference-in-differences analysis. PLoS medicine. 2017 Jun 13;14(6):e1002319.

3. Ye Y, Duah D. The President's Malaria Initiative contributed to reducing malaria burden in sub-Saharan Africa between 2004 and 2014: Evidence from generalized estimating equation analysis. PLoS one. 2019 May 24;14(5):e0217103.

4. Winskill P, Slater HC, Griffin JT, Ghani AC, Walker PG. The US President's Malaria Initiative, *Plasmodium falciparum* transmission and mortality: A modelling study. PLoS Medicine. 2017 Nov 21;14(11):e1002448.

5. Bhatt S, Weiss DJ, Cameron E, *et al*. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. Nature. 2015 Oct 8;526(7572):207-11.

6. World Health Organization. World Malaria Report 2024: addressing inequity in the global malaria response. Geneva: World Health Organization; 2024. Available from: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024

7. President's Malaria Initiative. 18th Annual Report to Congress. Washington, DC: President's Malaria Initiative; 2024. Available from: https://stacks.cdc.gov/view/cdc/154755

8. White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions – a systematic review. Malar J. 2011;10:337.

9. Penny MA, Verity R, Bever CA, *et al*. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016 Jan 23;387(10016):367-375. doi: 10.1016/S0140-6736(15)00725-4.

10. Bhatt S, Weiss DJ, Mappin B, *et al*. Coverage and system efficiencies of insecticide-treated nets in Africa from 2000 to 2017. Elife. 2015 Dec 29;4:e09672.

11. Bertozzi-Villa A, Bever CA, Koenker H, *et al*. Maps and metrics of insecticide-treated net access, use, and nets-per-capita in Africa from 2000-2020. Nature communications. 2021 Jun 11;12(1):3589.

12. The Malaria Atlas Project. Datasets available from: https://data.malariaatlas.org.

13. Weiss DJ, Dzianach PA, Saddler A, *et al*. Mapping the global prevalence, incidence, and mortality of *Plasmodium falciparum* and *Plasmodium vivax*, 2000–2022. Lancet. *In press.*

14. Roll Back Malaria. Programmatic and Financial Gap Analysis(v17/12/2024). Available from: https://dashboards. endmalaria.org/en/gap-analysis

15. Alliance for Malaria Prevention. AMP ITN Mass Campaign Tracker. Available from: https://allianceformalariaprevention.com/itn-dashboards/mass-campaign-tracker.

16. President's Malaria Initiative Malaria Operational Plans. Available at: http://pmi.gov/resources/

17. Nnaji C. Coverage and quality of seasonal malaria chemoprevention supported by Malaria Consortium with philanthropic funding or co-funding in 2023: results from Burkina Faso, Chad, Mozambique, Nigeria, South Sudan, Togo, and Uganda. Malaria Consortium; 2024. Available from: https://www.malariaconsortium.org/resources/publications/1774/coverage-and-quality-of-seasonal-malaria-chemoprevention-supported-by-malaria-consortium-in-2023.

18. Loua KM, Milligan P. Seasonal malaria chemoprevention in Guinea in 2020: coverage survey results. Technical Report. London: London School of Hygiene & Tropical Medicine, Universite Gamal Abdel Nasser; 2021. Available from: https://doi.org/10.17037/PUBS.04663123.

19. The PMI VectorLink Project. August 2023. Ethiopia 2023 End of Spray Report. Spray Campaign: May 2, 2023 – July 7, 2023. Rockville, MD: The PMI VectorLink Project, Abt Associates Inc

20. The PMI VectorLink Ghana Project. May 2023. Ghana End of Spray Report. Spray Campaign: March 1–April 13, 2023. Rockville, MD, USA: The PMI VectorLink Project, Abt Associates.

21. AngloGold Ashanti (Ghana) Malaria Control (AGAMal). (2023). Annual report 2023. AGAMal. Retrieved from https://www.agamal.org

22. ICF. The DHS Program. Available from: https://dhsprogram.com.

23. Mappin B, Cameron E, Dalrymple U, Weiss DJ, Bisanzio D, Bhatt S, Gething PW. Standardizing *Plasmodium falciparum* infection prevalence measured via microscopy versus rapid diagnostic test. Malaria journal. 2015 Dec;14:1-0.

24. Smith DL, Guerra CA, Snow RW, Hay SI. Standardizing estimates of the *Plasmodium falciparum* parasite rate. Malaria journal. 2007 Dec;6:1-0.

25. Rue H, Martino S, Chopin N. Approximate Bayesian inference for latent Gaussian models using integrated nested Laplace approximations (with discussion). Journal of the Royal Statistical Society, Series B, 71(2):319{392, 2009.

26. Lindgren F, Rue H, Lindström J. An explicit link between Gaussian fields and Gaussian Markov random fields: the stochastic partial differential equation approach. Journal of the Royal Statistical Society Series B: Statistical Methodology. 2011 Sep;73(4):423-98.

27. Cameron E, Battle KE, Bhatt S, *et al*. Defining the relationship between infection prevalence and clinical incidence of *Plasmodium falciparum* malaria. Nature communications. 2015 Sep 8;6(1):8170.

28. Nguyen M, Howes RE, Lucas TCD, Battle KE, *et al*. Mapping malaria seasonality in Madagascar using health facility data. BMC Med. 2020 Feb 10;18(1):26. doi: 10.1186/s12916-019-1486-3. PMID: 32036785; PMCID: PMC7008536.

29. Baba E, Ndiaye JL, Uaene R, *et al*. Effectiveness of seasonal malaria chemoprevention at scale in West and Central Africa: an observational study. Lancet. 2020;396(10265):1829-1840.

30. World Health Organization. World malaria report 2023. Geneva: World Health Organization; 2023. Available from: https://www.who.int/publications/i/item/9789240078121.

31. U.S. President's Malaria Initiative. Cameroon Malaria Operational Plan FY2024. Washington, DC: U.S. Agency for International Development; 2024.

32. U.S. President's Malaria Initiative. Nigeria Malaria Operational Plan FY2024. Washington, DC: U.S. Agency for International Development; 2024.

33. Ashton RA, Hamainza B, Lungu C, *et al*. Effectiveness of community case management of malaria on severe malaria and inpatient malaria deaths in Zambia: a dose–response study using routine health information system data. Malar J 22, 96 (2023). https://doi.org/10.1186/s12936-023-04525-2